Eric Topol

So congratulations on that.

It was a big move for you to leave the hardcore academics.

And the other thing I wanted to ask you, John, is

You had distinguished your career in immunology, in genetics, type 1 diabetes, and other autoimmune conditions, and now you've really diversified, as you described, with these different areas of emphasis at the new institute.

Is that more fun to do, or do you have helped deputies that you can

assigned to things like climate change and other areas.

It's fantastic.

I mean, you've really broadened and it's great that you have the runway to get these people on board.

And I think you're having a big building that's under construction.

Now, I assume it's pretty close to Oxford, and will you have some kind of interactions that are substantial?

Yeah, I love that model and the ability that you can go from small startups to really transformative companies have any impact.

It fits in well with the overall objectives.

I can see that.

The thing that also is intriguing regarding this whole effort is

is that in parallel, we've learned your influence.

The UK is a genomics world leader without any question.

And no coincidence that that's been your area of emphasis in your career.

So we've watched these three initiatives that I think you were involved in.

UK Biobank, which has had more impact than any cohort ever assembled.

Every day, there's another paper using that data.